Clinical Trials

NCT IdNCT04872621
TitleCalquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
ConditionRelapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
StudyTypeObservational
OrganizationAstraZeneca
Sponsor/CollaboratorsAstraZeneca
StatusNot yet recruiting
GenderAll
AgeGroupChild
Adult
Older Adult
Location (with distance)
DescriptionTo understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a real-world post-marketing setting.